About the company History Management team and Board Scientific advisors Business Development Career

Technology Platform Pipeline Stem cell therapy Cancer therapy Indications Publications

Share Information Owner List PDMR transactions Financial Calendar Reports Analyses Corporate Governance General Meetings Share Issues Subscribe IR-contact Certified Adviser

Press Releases Xintela in the news Newsletters Events Videos Subscribe Archive

About the company History Management team and Board Scientific advisors Business Development Career GDPR Policy

Technology Platform Pipeline Stem cell therapy Cancer therapy Indications Publications

Share information Owner list PDMR transactions Financial Calendar Reports Analyses Corporate Governance General Meetings Share Issues Subscribe IR-contact Certified Adviser

Press releases Xintela in the news Newsletters Events Videos Subscribe Press photos/logotypes Archive

CONTACT Svenska

Extra General Meeting - August 3, 2022

Stämmoprotokoll extra bolagsstämma 3 augusti 2022

Styrelsens redogörelse

Revisorns yttrande över styrelsens redogörelse för väsentliga händelser

Kallelse extra bolagsstämma 3 aug 2022

Formulär poströstning

Fullmaktsformulär

ABOUT XINTELA About the company History Management team and Board Scientific advisors Business Development Career possibilities

R&D Technology Platform Pipeline Stem cell therapy Cancer therapy Indications Publications

INVESTORS Extra AGM Share information Owners PDMR transactions Financial Calendar Reports Analyses Corporate Governance Share issue 2020 Subscribe IR contact Certified Adviser

NEWS & MEDIA Press releases Xintela in the news Newsletters Events Films Press photographs Subscribe Archive

Contact xintela ab

Medicon Village
SE-223 81 Lund, Sweden

+46 46 275 65 00

Reg. No: 556780-3480
VAT No: SE556780348001

Visiting address

Scheeletorget 1,
Lund, Sweden

Business & Administration

Evy Lundgren-Åkerlund
CEO
evy@xintela.se

IR & media